BioSpace News Archive

Genetic Screening Platform Technology and Data to Strengthen Entheon’s Psychedelic-Assisted Protocols.

Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced a licensing and supply agreement with TriLink Biotechnologies, part of Maravai LifeSciences (NASDAQ: MRVI), for its industryleading CleanCap® technology.

Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, recently announced that it has adjourned its Special Meeting of Shareholders (the “Special Meeting”) solely with respect to Proposal 1 set forth in its Definitive Proxy Statement (“Proxy Statement”) filed with the Securities and Exchange Commission on June 14, 2021.

Amgen (NASDAQ: AMGN) today announced that its Board of Directors declared a $1.76 per share dividend for the third quarter of 2021.

ReCode Therapeutics (the “Company”), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced preclinical data from the Company’s inhaled mRNA-based molecular therapy program for primary ciliary dyskinesia will be presented in an oral and poster presentation at the 2021 PCD on the Move Virtual Scientific Conference,

Spero Therapeutics, Inc. announced that on July 30, 2021, the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 114,600 shares of its common stock to ten new employees under the Spero Therapeutics, Inc.

Xoran Technologies announced that the company has commenced a clinical trial at St. Johns-Providence to document a series of cases using Xoran’s xCAT IQ mobile CT scanner.

Wilburn Medical USA is proud to announce that they have distributed their one millionth CareStart COVID-19 rapid test.

Radiology has emerged as a significant tool for diagnosis of several diseases and has played an extremely powerful role in the supervision of treatment and prediction of the outcome.

The global gemcitabine HCl market analysis by Fact.MR, a market research and competitive intelligence provider, is intended at updating stakeholders about key trends shaping growth prospects.